title: Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.
authors.affiliation: Institute for Cancer Research/The Royal Marsden NHS Foundation Trust, Centre for Cancer Therapeutics, Sutton, Surrey, UK. Gerhardt.attard@icr.ac.uk
authors.forename: Gerhardt
authors.initials: G
authors.lastname: Attard
authors.forename: Arie S
authors.initials: AS
authors.lastname: Belldegrun
authors.forename: Johann S
authors.initials: JS
authors.lastname: de Bono
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D059002:Androgen Receptor Antagonists; D000736:Androstenes; D000737:Androstenols / Q000627:therapeutic use*; D000818:Animals; D004341:Drug Evaluation; D006801:Humans; D008190:Lyases / Q000037:antagonists & inhibitors*; D008297:Male; D051379:Mice; D009362:Neoplasm Metastasis / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013254:Steroid 17-alpha-Hydroxylase / Q000502:physiology
chemical_list: D000726:Androgen Antagonists; D059002:Androgen Receptor Antagonists; D000736:Androstenes; D000737:Androstenols; D013254:Steroid 17-alpha-Hydroxylase; D008190:Lyases; C089740:abiraterone